Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence

Thyroid

Volumn 22, Issue 10, 2012, Pages 1007-1015

  Hugo, Jonathan ^a   Robenshtok, Eyal ^a,b   Grewal, Ravinder ^a   Larson, Steve ^a   Tuttle, R Michael ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 123; IODINE 131; RECOMBINANT THYROTROPIN;

ADULT; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIMODALITY CANCER THERAPY; ONCOCYTOMA; OUTCOME ASSESSMENT; POORLY DIFFERENTIATED THYROID CANCER; PRIORITY JOURNAL; RADIOACTIVE IODINE REMNANT ABLATION; RECURRENCE RISK; RETROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR ABLATION;

ABLATION TECHNIQUES; ADULT; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME;

EID: 84866990854     PISSN: 10507256     EISSN: 15579077     Source Type: Journal    
DOI: 10.1089/thy.2012.0183     Document Type: Review

References (25)

1. Barbaro D, Boni G 2007 Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when. Eur J Surg Oncol 33: 535-540. (Pubitemid 46746535)
2. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radio-iodine treatment with 30mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115. (Pubitemid 37153707)
3. Berg G, Lindstedt G, Suurkula M, Jansson S 2002 Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Invest 25:44-52. (Pubitemid 34168339)
4. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E 2009 Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 160: 431-436.
5. Lau WF, Zacharin MR, Waters K, Wheeler G, Johnston V, Hicks RJ 2006 Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. Intern Med J 36:564-570. (Pubitemid 44179831)
6. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87: 4063-4068.
7. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the fol-licular epithelium. Eur J Endocrinol 154:787-803. (Pubitemid 43997716)
8. 131I administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546. (Pubitemid 47435333)
9. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM 2002A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 43:1482-1488. (Pubitemid 35285874)
10. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86: 619-625. (Pubitemid 32207469)
11. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, Larson SM 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-869. (Pubitemid 32847944)
12. Rosario PW, Mineiro Filho AF, Lacerda RX, Calsolari MR 2012 Long-term follow-up of at least five years after re-combinant human thyrotropin compared to levothyroxine withdrawal for thyroid remnant ablation with radioactive iodine. Thyroid 22:332-333.
13. 131I in low-risk patients. Am J Clin Oncol 35:101-104.
14. 131I in high-risk patients. Thyroid 20:1247-1252.
15. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49: 764-770. (Pubitemid 351717542)
16. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S 2010 Radioactive iodine administered for thyroid remnant ablation following re-combinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20:257-263.
17. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW 2009 Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171-4179.
18. Tala H, Tuttle RM 2010 Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol (R Coll Radiol) 22:419-429.
19. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombi-nant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932. (Pubitemid 43357760)
20. Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM 2011 Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab 96:2105-2111.
21. Tuttle RM, Tala H, Shah J, Leboeuf R, Ghossein R, Gonen M, Brokhin M, Omry G, Fagin JA, Shaha A 2010 Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20:1341-1349.
22. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214.
23. Nixon IJ, Ganly I, Patel S, Palmer FL, Whitcher MM, Tuttle RM, Shaha AR, Shah JP 2011 The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery 150:1242-1249.
24. Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, Pacini F 2011 Delayed risk stratification, to include the response to initial treatment (surgery and radio-iodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol 165:441-446.
25. Klubo-Gwiezdzinska J, Burman KD, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L 2012 Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid 22:310-317.